🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gastric Adenocarcinoma
Clinical trial register · China

Gastric Adenocarcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 12 Guangzhou 8 Nanjing 7 Zhengzhou 5 Shanghai 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University4 Cancer Institute and Hospital, Chinese Academy of Medical Sciences3 Fudan University3 Nanfang Hospital, Southern Medical University2 Tianjin Medical University Cancer Institute and Hospital2
Site location
Beijing12 Guangzhou8 Nanjing7 Zhengzhou5 Shanghai4
All 23 locations
Target enrolment
to

Gastric Adenocarcinoma trials in China

43 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
NCT07799649Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Observational
150
Nanjing
2026-09
Not yet open
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07701681ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
DrugsTagitanlimab·Sacituzumab tirumotecan
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Not yet open
Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction
NCT07800819Gastric Adenocarcinoma, Adenocarcinoma of the Esophagogastric Junction
The First Affiliated Hospital with Nanjing Medical University
Observational
250
Nanjing
2026-08-15
Not yet open
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
NCT07655661Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsOxaliplatin·Capecitabine·Tislelizumab
Ming Liu
Phase 2
52
Chengdu
2026-07-01
Not yet open
Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
NCT07621562Gastric Adenocarcinoma, Esophagogastric Juction Cancer, Proficient Mismatch Repair
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou
2026-06-05
Not yet open
Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07603349Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2/3
405
Guangzhou
2026-06
Recruiting
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07584135Gastric Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd
Phase 3
600
Guangzhou
2026-05-28
Active, closed
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
NCT07776639Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsTegafur Gimeracil Oteracil·Iparomlimab and Tuvonralimab·Oxaliplatin·Paclitaxel
Yongxu Jia
Phase 2
34
Zhengzhou
2026-05-10
Not yet open
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
NCT07610629Gastric Adenocarcinoma
DrugsRetlirafusp alfa·Apatinib·Nab-paclitaxel
Henan Cancer Hospital
Phase 2
50
Zhengzhou
2026-05-05
Recruiting
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
NCT07464756Gastric Adenocarcinoma
DrugsS-1 & Oxaliplatin·SHR-1701·Apatinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2026-04-03
Not yet open
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
NCT07507526Gastric Adenocarcinoma
Sun Yat-sen University
Phase 2
76
Guangzhou
2026-04
Not yet open
An Observational Study on Gastric Cancer in High-risk Individuals
NCT07438418Gastric Adenocarcinoma
Fudan University
Observational
3,000
Tongling
2026-01-31
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
NCT07263386Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
460
Nanjing
2025-10-23
Recruiting
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
NCT07007182Gastric Adenocarcinoma, Stomach Neoplasms
DrugCapeox
Jinbo Yue
Phase 2
54
Jinan
2025-10-01
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07152405Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugBL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
NCT07103668Gastric Adenocarcinoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase 3
150
Beijing
2025-08-06
Recruiting
Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection
NCT06943781Gastric Adenocarcinoma, Helicobacter Pylori
Fudan University
Observational
15,000
Tongling
2025-07-01
Recruiting
Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
NCT07029269Gastric Adenocarcinoma, Laparoscopic Gastrectomy, Complications
Zuoyi Jiao
Phase 3
454
Beijing, Fuzhou, Lanzhou, Zhejiang, Xi'an
2025-06-16
Recruiting
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
NCT07034742Gastric Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
136
Beijing
2025-06-01
Recruiting
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
NCT06985602Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2
30
Nanjing
2025-05-16
Active, closed
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06914687Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis
Fudan University
Phase 2
30
Shanghai
2025-04-15
Not yet open
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
NCT06888037Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy
Ruijin Hospital
Phase 2
55
Shanghai
2025-03-31
Not yet open
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients
NCT06857786Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Peking University
Phase 1
48
Beijing, Nanjing
2025-03-10
Not yet open
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
NCT06871527Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
DrugsFolfox·Fruquintinib·Tislelizumab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2
44
Guangzhou
2025-03-01
Active, closed
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy
NCT06938139Gastric Adenocarcinoma, Surgery, Laparoscopic
Fujian Medical University
Observational
90,000
Fuzhou
2025-03-01
Recruiting
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
NCT06808971Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
61
Beijing
2025-02-28
By invitation
Laparoscopic Staging for Stage III Gastric Cancer
NCT07533825Gastric Cancer (GC), Gastric Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
968
Tianjin
2025-02-01
Recruiting
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
NCT06761846Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
70
Beijing
2025-01-17
Recruiting
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
NCT06798376Gastric Adenocarcinoma
Chinese PLA General Hospital
Observational
300
Beijing
2025-01-16
Recruiting
The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
NCT06881043Locally Advanced Gastric Cancer, Gastric Adenocarcinoma
The First Hospital of Jilin University
Observational
300
Changchun
2024-11-20
Active, closed
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT06667050Gastric Adenocarcinoma
West China Hospital
Phase 2
58
Chengdu
2024-10-10
Not yet open
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
NCT06586294Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 1/2
294
Hanzhou
2024-09-10
Not yet open
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
NCT06454435Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsTegafur Gimeracil Oteracil·Nab-paclitaxel·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
158
Tianjin
2024-06
Recruiting
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
NCT06196697Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Phase 2
50
Harbin
2024-04-10
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Active, closed
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
NCT06206733Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsASKB589·Oxaliplatin·Capecitabine·Tislelizumab
AskGene Pharma, Inc.
Phase 3
780
Beijing
2024-01-25
Recruiting
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugsASP2138·Ramucirumab·Leucovorin·Irinotecan
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Trastuzumab·Paclitaxel
ALX Oncology Inc.
Phase 2/3
127
2022-01-15
Recruiting
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
NCT04850729Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
Observational
169
Guangzhou
2021-05-25
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Recruiting
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NCT04047953Gastric Adenocarcinoma
DrugsOxaliplatin and S-1·Paclitaxel
Peking University Cancer Hospital & Institute
Not applicable
95
Beijing
2019-09-10
Active, closed
Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma
NCT03691454Gastric Adenocarcinoma
Peking University
Phase 2/3
248
Beijing
2018-06-28
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/gastric-adenocarcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies listing the condition Gastric Adenocarcinoma.

How many Gastric Adenocarcinoma trials are recruiting in China?

19 of the 43 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 14 have not yet opened recruitment, 9 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastric Adenocarcinoma), 43 studies
PhaseStudiesRecruitingShare
Phase 217739.5%
Observational8418.6%
Phase 1/25111.6%
Phase 35411.6%
Phase 2/3307%
Not applicable214.7%
Phase 1214.7%
Phase EARLY_PHASE1112.3%

Most active sponsors

Lead sponsors with the most studies (Gastric Adenocarcinoma)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital with Nanjing Medical University42
Cancer Institute and Hospital, Chinese Academy of Medical Sciences33
Fudan University31
Henan Cancer Hospital21
Nanfang Hospital, Southern Medical University21
Peking University20
Sun Yat-sen University20
Tianjin Medical University Cancer Institute and Hospital20
Akeso10
ALX Oncology Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.